



1647

Atty. Dkt. No. 038602-1259

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Axel ULLRICH et al.
Title: NOVEL MEGAKARYOCYTIC
PROTEIN TYROSINE KINASES
Appl. No.: 09/977,261
Filing Date: October 16, 2001
Examiner: Seharaseyon, Jegatheesan
Art Unit: 1647

RECEIVED
JUL 21 2003
TECH CENTER 1600/2900

AMENDMENT TRANSMITTAL

Mail Stop NON-FEE AMENDMENT
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☐ Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.
- ☐ Small Entity statement is enclosed.
- ☒ The fee required for additional claims is calculated below:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	13	20	0	x \$18.00	\$0.00
Independents:	7	7	0	x \$84.00	\$0.00
First presentation of any Multiple Dependent Claims:				+ \$280.00	\$0.00
CLAIMS FEE TOTAL:					\$0.00

- ☐ Applicant hereby petitions for an extension of time under 37 C.F.R. § 1.136(a) for the total number of months checked below:

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$410.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the third month:	\$930.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,450.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,970.00	\$0.00
	EXTENSION FEE TOTAL:		\$0.00
<input type="checkbox"/>	Statutory Disclaimer Fee under 37 C.F.R. 1.20(d):	\$110.00	\$0.00
	CLAIMS, EXTENSION AND DISCLAIMER FEE TOTAL:		\$0.00
<input type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$0.00
	TOTAL FEE:		\$0.00

☐ Please charge Deposit Account No. 19-0741 in the amount of \$0.00. A duplicate copy of this transmittal is enclosed.

☐ A check in the amount of \$0.00 is enclosed.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Date

7/18/03

FOLEY & LARDNER

Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5475

Facsimile: (202) 672-5399

Respectfully submitted,

By

Beth A. Burrous

Attorney for Applicant

Registration No. 35,087



ATTY. DKT. No. 038602/1259
APPLICATION SERIAL No. 09/977,261

#11/B
2-24-03
Dome

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Axel ULLRICH et al.
Title: NOVEL MEGAKARYOCYTIC PROTEIN TYROSINE KINASES
Appl. No.: 09/977,261
Appl. Filing Date: October 16, 2001
Examiner: Seharaseyon, Jegatheesan
Art Unit: 1647

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

RECEIVED

JUL 21 2003

TECH CENTER 1600/2900

In reply to the Office Action mailed on June 18, 2003, please enter the following amendments and remarks. Since this response is filed before the end of the thirty (30) day shortened statutory period, *i.e.*, July 18, 2003, Applicants consider this paper to be timely filed. Nevertheless, should additional fees and a petition be necessary to prevent abandonment of this application, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 and consider this paper a request for a petition for extension of time.

The amendments presented below comply with the revised amendment format permitted by the Notice from the Office of Patent Legal Administration of the U.S. Patent and Trademark Office dated February 10, 2003. Thus, the provisions of 37 C.F.R. § 1.121(a), (b), (c) and (d) are waived for amendments made to the claims, specification and drawings of this application.

Amendments to the claims begin at page 2.

The Remarks begin at page 3.